MedTrace Logo

Randomized Trial of Beta-Carotene and Macular Degeneration

NCT00000152 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982.

To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E.

To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.

Conditions

  • Macular Degeneration

Interventions

DRUG

Aspirin

DRUG

Beta-Carotene

Sponsors & Collaborators

  • National Eye Institute (NEI)

    lead NIH

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION

Eligibility

Min Age
40 Years
Max Age
84 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1982-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000152 on ClinicalTrials.gov